According to the market research, the sales of Capecitabine in the Chinese market increased year by year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on the hospital's overall diagnosis and treatment services, sales in 2020 decreased to CNY 914 million, a year-on-year decrease of 9.31%. The CAGR of Capecitabine sales in the Chinese market from 2016 to 2020 is 1.21%.
The analyst expects that with the easing of the COVID-19 pandemic, the sales of Capecitabine in the Chinese market will have a restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million, and the number of colon cancers reached 1.93 million, both of which were on the rise. The number of breast and colon cancers in China will be also on the rise in the future. Therefore, the sales volume of Capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase with the increase in the number of breast cancer and colon cancer patients in China. There is also room for sales to rise. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already reported for Capecitabine generic drug approval. In the next few years, more manufacturers will join the Chinese market. The sales volume and sales of Capecitabine in China are expected to rise.
Topics Covered:
- The impact of COVID-19 on China's Capecitabine market
- Sales value of China's Capecitabine 2016-2020
- Competitive landscape of China's Capecitabine market
- Prices of Capecitabine in China
- Prices of Capecitabine in China by regions and manufacturers
- Analysis on factors affecting the development of China's Capecitabine market
- Prospect of China's Capecitabine market from 2021 to 2025
Table of Contents
Samples
LOADING...
Companies Mentioned
- Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
- Jiangsu Hengrui Medicine Co,.Ltd. (Aibin)
- Qilu Pharmaceutical Co., Ltd. (Zuolun)
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
- Hoffmann-La Roche Inc (XELODA)
Methodology
Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.
Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.
Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.
The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.
The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.
1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 50 |
Published | July 2021 |
Forecast Period | 2016 - 2025 |
Estimated Market Value ( CNY | CNY 871.49 Million |
Forecasted Market Value ( CNY | CNY 1611.57 Million |
Compound Annual Growth Rate | 7.0% |
Regions Covered | China |
No. of Companies Mentioned | 5 |